COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 1015: Articles 10141-10150  | Next

Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H., Doolman, R., Asraf, K., Rubin, C., Fluss, R., Mendelson, E., Freedman, L., Regev-Yochay, G., Kreiss, Y.
10.1101/2021.12.19.21268037 — Posted: 2021-12-21
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
Chew, K. W., Moser, C., Daar, E. S., Wohl, D. A., Li, J. Z., Coombs, R., Ritz, J., Giganti, M., Javan, A. C., Li, Y., Malvestutto, C., Klekotka, P., Price, K., Nirula, A., Fischer, W., Bala, V., Ribeiro, R., Perelson, A. S., Fletcher, C. V., Eron, J. J., Currier, J. S., Hughes, M. D., Smith, D. M.
10.1101/2021.12.17.21268009 — Posted: 2021-12-21
Comparative effectiveness of the BNT162b2 vs ChAdOx1 vaccine against Covid-19
Xie, J., feng, s., Li, X., Gea Mallorqui, E., Prats-Uribe, A., PRIETO-ALHAMBRA, D.
10.1101/2021.12.18.21268039 — Posted: 2021-12-21
Keeping doors open: A cross-sectional survey of family physician practice patterns during COVID-19, needs, and intentions
Kiran, T., Wang, R., Handford, C., Laraya, N., Eissa, A., Pariser, P., Brown, R., Pedersen, C.
10.1101/2021.12.20.21267918 — Posted: 2021-12-21
Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26.COV2.S vaccine trial, South Africa
Goga, A. E., Bekker, L.-G., Garret, N., Reddy, T., Yende-Zuma, N., Fairall, L., Moultrie, H., Takalani, A., Trivelli, V., Faesen, M., Baley, V., Seocharan, I., Gray, G. E.
10.1101/2021.12.21.21268171 — Posted: 2021-12-21
Quantitative detection of SARS-CoV-2 Omicron variant in wastewater through allele-specific RT-qPCR
Lee, W. L., Gu, X., Armas, F., Wu, F., Chandra, F., Chen, H., Xiao, A., Leifels, M., Chua, D. F. J., Kwok, G. W. C., Tay, J. Y. R., Lim, C. Y. J., Thompson, J., Alm, E. J.
10.1101/2021.12.21.21268077 — Posted: 2021-12-21
SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant
Yang, W., Shaman, J.
10.1101/2021.12.19.21268073 — Posted: 2021-12-21
Rapid rise in paediatric COVID-19 hospitalisations during the early stages of the Omicron wave, Tshwane District, South Africa
Cloete, J., Kruger, A., Masha, M., du Plessis, N. M., Mawela, D., Tshukudu, M., Manyane, T., Komane, L., Venter, M., Jassat, W., Goga, A., Feucht, U.
10.1101/2021.12.21.21268108 — Posted: 2021-12-21
Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December 2021
Eggink, D., Andeweg, S. P., Vennema, H., van Maarseveen, N., Vermaas, K., Vlaemynck, B., Schepers, R., van Gageldonk-Lafeber, A. B., van den Hof, S., Reusken, C. B. E. M., Knol, M. J.
10.1101/2021.12.20.21268121 — Posted: 2021-12-21
Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients
Madelon, N., Heikkila, N., Sabater Royo, I., Fontannaz, P., Breville, G., Lauper, K., Goldstein, R., Grifoni, A., Sette, A., Siegrist, C.-A., Finckh, A., Lalive, P. H., Didierlaurent, A. M., Eberhardt, C. S.
10.1101/2021.12.20.21268128 — Posted: 2021-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).